Immune gene therapy of cancer

Akbulut, Hakan

doi:10.3906/sag-2005-327

Cited by 13 publications

(6 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor cells can play a crucial role in disease development through different immune mechanisms. Immune-related genes have been shown to play a role in cancer development (6)(7)(8) and, in some studies, can also can predict the prognosis of cancer patients and as therapeutic targets (9)(10)(11)(12). In addition to being an effective prognostic biomarker by constructing the immune prognostic features of cancer using bioinformatics, it is also a promising and novel therapeutic target.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the regulatory mechanisms of prognostic immune factors in thyroid cancer

2022

View full text Add to dashboard Cite

ObjectiveTo explore the regulatory mechanism of immune prognostic factors in thyroid cancer.MethodsBased on the TCGA database and GEO database, this study used bioinformatics methods to study the potential regulatory mechanism of thyroid cancer prognosis, analyzed the differentially expressed genes and differential miRNAs between thyroid cancer and normal paracancerous tissues by R software, and constructed lasso risk factors. The immune prognostic factors of thyroid cancer were obtained from the model, and the miRDB website was used to predict the possibility of differential miRNA target binding of the immune prognostic factors and correlation analysis was performed, and finally verified by cell experiments.ResultsThere were 1413 differentially expressed genes between thyroid cancer and normal paracancerous tissues, among which 21 immune-related genes were prognostic factors with significant differences in expression; lasso risk model obtained AKAP12, APOC1, TIMP3, ADAMTS9, ANK2, HTRA3, SYNDIG1 , ADAMTS5 and DACT1 were nine prognostic factors. A total of 58 differential miRNAs were found in thyroid cancer tissues and non-cancerous tissues. The possibility of differential miRNA targeting and binding of immune prognostic factors on the miRDB website and cell experiments was analyzed.ConclusionsThe potential miRNA regulatory mechanism of immune prognostic factors in thyroid cancer has been explored.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of the regulatory mechanisms of prognostic immune factors in thyroid cancer

2022

View full text Add to dashboard Cite

show abstract

“…Although T cells do not possess a functional receptor for GM-CSF and thus do not rely on GM-CSF for proliferation and anti-tumor activity ( 14 ), one study in mice did show effect of GM-CSF on the anti-tumor properties of mouse CAR T-cell ( 15 ). In another study cancer cells transduced with an adenoviral vector carrying GM-CSF have induced strong antitumor immunity against tumor cells and prevented tumor regrowth in animal models ( 16 ). Therefore, we try to use GM-CSF to treat neutropenia in order to gain better anti-tumor effect of CAR T-cell and better host immunity against infection.…”

Section: Discussionmentioning

confidence: 99%

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome

et al. 2022

View full text Add to dashboard Cite

BackgroundNeutropenia and cytokine release syndrome (CRS) are two major toxicities of chimeric antigen receptor (CAR)-T cell therapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an ideal candidate treatment for neutropenia except for its potential aggravation of CRS. We hypothesized that the optimal timing of supplemental with GM-CSF in a shortage of host immunity and CAR T-cell was chosen as avoidance of CRS. In the study we evaluated the safety and efficacy of GM-CSF intervention post-CAR T-cell therapy while circulating CAR T-cell declined.Materials and methodsNine patients received GM-CSF therapy who displayed moderate neutropenia with absolute neutrophil counts (ANC) < 1,500 cells/mm3 with concomitant declination of circulating CAR T-cell.ResultsThe median duration of GM-CSF intervention was 15 days (4–30). CAR T-cell expansion was observed in peripheral blood (PB) of seven patients (7/9). The median baseline and peak CAR T cells count in PB of the seven patients with CAR T-cell expansion were 0.85 × 106/L (0–50.9) and 6.06 × 106/L (1.43–112.55). And the peaks of CAR T-cell levels in PB appeared in day 7 (2–11) following the initiation of GM-CSF administration with increases of 2.84 × 106/L (0.38–61.65). Also, increased white blood cells in PB were observed in all patients. The median onset and duration time of WBC recovery were 9 (1–14) and 17 (3–53) days. Moreover, the increment of WBC, neutrophil, lymphocyte and CD3-CD16 + CD56 + natural killer cell in PB was observed. In addition, no CRS or fatal infection occurred during GM-CSF treatment.ConclusionThis study provides evidence for the clinical feasibility of combining CAR T-cell therapy with the GM-CSF to treat neutropenia patients with concomitant declination of circulating CAR T-cell.

show abstract

“…The main immune targets of cancer gene therapy are cytokine/chemokine genes, tumor-related antigens, and fusion proteins, including tumor antigens, genetically modified tumor cells, or immune cells, among which the immune gene therapy of cytokinesis is more prominent [ 62 ]. Cytokines have pleiotropic effects, which mediate systemic and local biological effects.…”

Section: Different Strategies Of Ovs-based Gene Therapy Of Liver Cancermentioning

confidence: 99%

Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer

Zhang,

Xiao,

Zhang

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Liver cancer is a major malignant tumor, which seriously threatens human health and increases the economic burden on patients. At present, gene therapy has been comprehensively studied as an excellent therapeutic measure in liver cancer treatment. Oncolytic virus (OV) is a kind of virus that can specifically infect and kill tumor cells. After being modified by genetic engineering, the specificity of OV infection to tumor cells is increased, and its influence on normal cells is reduced. To date, OV has shown its effectiveness and safety in experimental and clinical studies on a variety of tumors. Thus, this review primarily introduces the current status of different genetically engineered OVs used in gene therapy for liver cancer, focuses on the application of OVs and different target genes for current liver cancer therapy, and identifies the problems encountered in OVs-based combination therapy and the corresponding solutions, which will provide new insights into the treatment of liver cancer.

show abstract

Immune gene therapy of cancer

Cited by 13 publications

References 83 publications

Analysis of the regulatory mechanisms of prognostic immune factors in thyroid cancer

Analysis of the regulatory mechanisms of prognostic immune factors in thyroid cancer

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome

Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer

Contact Info

Product

Resources

About